Graftskin, a Human Skin Equivalent, Is Effective in the Management of Noninfected Neuropathic Diabetic Foot Ulcers
Author:
Veves Aristidis1, Falanga Vincent1, Armstrong David G.1, Sabolinski Michael L.1,
Affiliation:
1. From the Joslin-Beth Israel Deaconess Foot Center and Harvard Medical School (A.V.), Boston, Massachusetts; the Department of Dermatology and Skin Surgery (V.F.), Roger Williams Medical Center, Providence, Rhode Island; the Boston University School of Medicine (V.F.), Boston, Massachusetts; the Department of Surgery (D.G.A.), Southern Arizona Veterans Affairs Medical Center, Tucson, Arizona; and Organgenesis (M.L.S.), Canton,Massachusetts.
Abstract
OBJECTIVE— We assessed in a randomized prospective trial the effectiveness of Graftskin, a living skin equivalent, in treating noninfected nonischemic chronic plantar diabetic foot ulcers.
RESEARCH DESIGN AND METHODS— In 24 centers in the U.S., 208 patients were randomly assigned to ulcer treatment either with Graftskin (112 patients) or saline-moistened gauze (96 patients, control group). Standard state-of-the-art adjunctive therapy, which included extensive surgical debridement and adequate foot off-loading, was provided in both groups. Graftskin was applied at the beginning of the study and weekly thereafter for a maximum of 4 weeks (maximum of five applications) or earlier if complete healing occurred. The major outcome of complete wound healing was assessed by intention to treat at the 12-week follow-up visit.
RESULTS— At the 12-week follow-up visit, 63 (56%)Graftskin-treated patients achieved complete wound healing compared with 36(38%) in the control group (P = 0.0042). The Kaplan-Meier median time to complete closure was 65 days for Graftskin, significantly lower than the 90 days observed in the control group (P = 0.0026). The odds ratio for complete healing for a Graftskin-treated ulcer compared with a control-treated ulcer was 2.14 (95% CI 1.23-3.74). The rate of adverse reactions was similar between the two groups with the exception of osteomyelitis and lower-limb amputations, both of which were less frequent in the Graftskin group.
CONCLUSIONS— Application of Graftskin for a maximum of 4 weeks results in a higher healing rate when compared with state-of-the-art currently available treatment and is not associated with any significant side effects. Graftskin may be a very useful adjunct for the management of diabetic foot ulcers that are resistant to the currently available standard of care.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference24 articles.
1. Reiber GE, Boyko EJ, Smith DG: Lower extremity foot ulcers and amputations in diabetes. In Diabetes in America. 2nd ed. National Diabetes Data Group, Ed. Washington, DC, National Institutes of Health, 1995, p. 409-428 2. American Diabetes Association: Diabetes 1993: Vital Statistics. Alexandria, VA, American Diabetes Association,1993 3. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE,Wagner EH: Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 22:382-387, 1999 4. Edmonds ME, Blundell MP, Morris ME, Thomas EM, Cotton LT, Watkins PJ: Improved survival of the diabetic foot: the role of a specialist foot clinic. QJ Med 232:763-771, 1986 5. Pecoraro RE, Reiber GE, Burgess EM: Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 13: 513-521,1990
Cited by
611 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|